Can-Fite BioPharma Ltd. (CANF)
CANF Price and Sentiment
CANF Latest news
Can-Fite's Findings on Cannabis Compound's Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD's The Liver Meeting® 2021 Conference
2021-11-01 07:00PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite's Findings on Cannabis Compound's Inhibition of Liver Cancer Published in HEPATOLOGY and will be Presented at the AASLD's The Liver Meeting®
Can-Fite's NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico
2021-10-28 07:00PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that its patent titled "An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation" has been granted in Hong Kong and Mexico, and has received a notice of allowance in Japan. This patent addresses the use of the A3 Adenosine Recept
Can-Fite CEO to Present Namodenoson's Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit
2021-10-26 07:00PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite CEO to Present Namodenoson's Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
2021-10-21 09:25PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that Alimentary Pharmacology & Therapeutics, a peer reviewed scientific journal focused on gastroenterology and hepatology, published an article titled “Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis" authored by Can-Fite's CEO Dr. Pnina Fishman.
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
2021-10-21 07:00PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that Alimentary Pharmacology & Therapeutics, a peer reviewed scientific journal focused on gastroenterology and hepatology, published an article titled “Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatt
Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021
2021-10-05 07:00PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021
Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences
2021-09-17 07:00PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences
Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
2021-09-09 07:00PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study
2021-09-02 07:00PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study
Can-Fite Reports Drop In H1 2021 Revenue, Net Loss Down By 38% YoY
2021-08-26 12:48Biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI) announced its financial results Thursday for the quarter ended June 30, 2021.